KalVista Pharmaceuticals, Inc. - Common Stock —— 财务报表 (NASDAQ:KALV) | MetaTrader

展开完整图表完整图表

新闻

KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too

KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive (KALV)

KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript

KalVista Pharmaceuticals Stock Sees RS Rating Jump To 86

KalVista公布sebetralstat数据,显示早期治疗效果

KalVista presents sebetralstat data showing early treatment impact

KalVista Pharma首席财务官Piekos出售价值27,506美元股票

KalVista Pharma首席医疗官Audhya出售8.3万美元股票

KalVista Pharma首席商务官Sweeny出售6.19万美元股票

KalVista Pharma首席开发官出售6.77万美元股票

KalVista Pharma首席执行官Palleiko出售15.6万美元股票以履行纳税义务

Wall Street Analysts Think KalVista Pharmaceuticals (KALV) Could Surge 117.1%: Read This Before Placing a Bet